Can we use genetic engineering to help the body’s immune system target cancer cells? This is exactly what happens with CAR-T (chimeric antigen receptor) T-cell therapy. CAR-T cells are T-cells, immune cells of the body that are reprogrammed to identify specific surface signatures that define specific types of cancer cells. It allows these immune agents to seek and destroy cancer cells with great accuracy and with fewer side effects to traditional chemotherapy or radiation. While in their infancy, these techniques show great promise for future therapies. Today’s guest is Dr. Joe Fraietta, a leader in CAR-T cell solutions. He explains how the technology works, describes its applications and future uses. # COLABRA Talking Biotech is brought to you by Colabra – an R&D platform that brings your lab’s world-changing research together in one shared space. Learn more at https://www.colabra.app/ # TALKING BIOTECH Twitter: https://twitter.com/talkingbiotech Website: https://www.colabra.app/podcasts/talking-biotech/ Instagram: https://www.instagram.com/colabrahq The Talking Biotech podcast is distinct from Dr. Kevin Folta's teaching and research roles at the University of Florida. The views expressed on the show are those of Dr. Folta and his guests, and do not reflect the opinions of the university or Colabra.